Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitomycin ophthalmic - Mobius Therapeutics

Next Previous
Search
Drug Profile

Mitomycin ophthalmic - Mobius Therapeutics

Alternative Names: Mitomycin-c ophthalmic solution - Mobius Therapeutics; Mitosol

Latest Information Update: 05 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mobius Therapeutics
  • Developer Leiters; Mobius Therapeutics
  • Class Amines; Antiglaucomas; Antineoplastics; Aza compounds; Aziridines; Carbamates; Cytostatic antibiotics; Eye disorder therapies; Glucosidases; Heterocyclic compounds with 4 or more rings; Indoles; Mitomycins; Pyrroles; Recombinant proteins; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corneal disorders; Recurrent pterygium; Glaucoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma
  • Preregistration Corneal disorders; Recurrent pterygium

Most Recent Events

  • 03 Jan 2023 Mobius Therapeutics receives patent issuance for mitomycin ophthalmic (Mitosol®) in the US
  • 14 Feb 2019 Mobius Therapeutics enters into sales and marketing agreement with Leiters for Mitomycin ophthalmic (Mitosol®) in USA
  • 09 Oct 2018 Mitomycin ophthalmic (Mitosol®) is still in preregistration phase and awaiting regulatory approval from the USFDA for Recurrent pterygium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top